Sputnik V Vaccine Demonstrates 97.6% Efficacy in Russia

Strategic Insights -

Researchers at the Gamaleya National Research Center of Epidemiology and Microbiology in collaboration with the Russian Direct Investment Fund (RDIF) have announced the efficacy of the Sputnik V vaccine, affirming its effectiveness in preventing COVID-19. The study analyzed data from over 3.8 million Russians vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021. The infection rate among those vaccinated was only 0.027%, while the incidence among the unvaccinated adult population was 1.1% for a comparable period. The vaccine's efficacy was calculated using a formula and will be published in a peer-reviewed medical journal in May.

Key Takeaways:

  • The Sputnik V vaccine demonstrated efficacy of 97.6% in preventing COVID-19, based on the analysis of infection rates among those vaccinated with both components of the vaccine.
  • The study involved a dataset of over 3.8 million Russians who were vaccinated from December 5, 2020 to March 31, 2021, and the results show that the infection rate among those vaccinated was significantly lower than the unvaccinated population.
  • The vaccine's efficacy was calculated using a formula that compared the infection rate among the vaccinated population to the unvaccinated population.
  • The Sputnik V vaccine uses a two-shot course, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
  • The vaccine has been approved for use in 60 countries with a total population of 3 billion people, ranking second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.
  • Alexander Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology, stated that the actual efficacy of the vaccine may even be higher than the calculated results.
  • Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented that the data confirms that Sputnik V demonstrates one of the best protection rates against coronavirus among all vaccines.

Statistics:

  • Infection rate among vaccinated population: 0.027%
  • Incidence among unvaccinated adult population: 1.1%
  • Number of vaccinations analyzed: over 3.8 million
  • Total countries approving Sputnik V: 60 countries with a total population of 3 billion
  • Number of approvals issued by government regulators: second among coronavirus vaccines globally

Sources:

  • Gamaleya National Research Center of Epidemiology and Microbiology
  • Russian Direct Investment Fund (RDIF)
  • The Lancet medical journal
  • Gamaleya Research Institute of Epidemiology and Microbiology
  • Russian Direct Investment Fund (RDIF) website